The effect of antibody blockade of CTLA-4 and PD-1 in AML has been analyzed in different clinical trials with preliminary results showing lower success rates in comparison with those obtained in solid cancer [27, 28]. The gene discussed is PDCD1; the disease is acute myeloid leukemia.